These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29140444)

  • 21. Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.
    Lindesmith LC; Mallory ML; Jones TA; Richardson C; Goodwin RR; Baehner F; Mendelman PM; Bargatze RF; Baric RS
    J Infect Dis; 2017 Mar; 215(6):984-991. PubMed ID: 28453838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial.
    López P; López-Medina E; Sáez-Llorens X; deAntonio R; Masuda T; Mendelman PM; Sherwood J; Baehner F; Borkowski A
    Hum Vaccin Immunother; 2023 Dec; 19(1):2204787. PubMed ID: 37140558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.
    Bernstein DI; Atmar RL; Lyon GM; Treanor JJ; Chen WH; Jiang X; Vinjé J; Gregoricus N; Frenck RW; Moe CL; Al-Ibrahim MS; Barrett J; Ferreira J; Estes MK; Graham DY; Goodwin R; Borkowski A; Clemens R; Mendelman PM
    J Infect Dis; 2015 Mar; 211(6):870-8. PubMed ID: 25210140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Exploratory Study of the Salivary Immunoglobulin A Responses to 1 Dose of a Norovirus Virus-Like Particle Candidate Vaccine in Healthy Adults.
    Atmar RL; Cramer JP; Baehner F; Han C; Borkowski A; Mendelman PM
    J Infect Dis; 2019 Jan; 219(3):410-414. PubMed ID: 30203081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.
    Tamminen K; Malm M; Vesikari T; Blazevic V
    Viral Immunol; 2016 Jun; 29(5):315-9. PubMed ID: 27135874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity studies in animal models support clinical development of a bivalent norovirus-like particle vaccine produced in plants.
    Tusé D; Malm M; Tamminen K; Diessner A; Thieme F; Jarczowski F; Blazevic V; Klimyuk V
    Vaccine; 2022 Feb; 40(7):977-987. PubMed ID: 35063285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Norovirus vaccine against experimental human Norwalk Virus illness.
    Atmar RL; Bernstein DI; Harro CD; Al-Ibrahim MS; Chen WH; Ferreira J; Estes MK; Graham DY; Opekun AR; Richardson C; Mendelman PM
    N Engl J Med; 2011 Dec; 365(23):2178-87. PubMed ID: 22150036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults.
    Landrum ML; Lalani T; Niknian M; Maguire JD; Hospenthal DR; Fattom A; Taylor K; Fraser J; Wilkins K; Ellis MW; Kessler PD; Fahim RE; Tribble DR
    Hum Vaccin Immunother; 2017 Apr; 13(4):791-801. PubMed ID: 28010246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
    Reisinger EC; Tschismarov R; Beubler E; Wiedermann U; Firbas C; Loebermann M; Pfeiffer A; Muellner M; Tauber E; Ramsauer K
    Lancet; 2019 Dec; 392(10165):2718-2727. PubMed ID: 30409443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
    Harro CD; Pang YY; Roden RB; Hildesheim A; Wang Z; Reynolds MJ; Mast TC; Robinson R; Murphy BR; Karron RA; Dillner J; Schiller JT; Lowy DR
    J Natl Cancer Inst; 2001 Feb; 93(4):284-92. PubMed ID: 11181775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
    Modjarrad K; Roberts CC; Mills KT; Castellano AR; Paolino K; Muthumani K; Reuschel EL; Robb ML; Racine T; Oh MD; Lamarre C; Zaidi FI; Boyer J; Kudchodkar SB; Jeong M; Darden JM; Park YK; Scott PT; Remigio C; Parikh AP; Wise MC; Patel A; Duperret EK; Kim KY; Choi H; White S; Bagarazzi M; May JM; Kane D; Lee H; Kobinger G; Michael NL; Weiner DB; Thomas SJ; Maslow JN
    Lancet Infect Dis; 2019 Sep; 19(9):1013-1022. PubMed ID: 31351922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial.
    Leroux-Roels G; Clément F; Vandepapelière P; Fourneau M; Heineman TC; Dubin G
    Hum Vaccin Immunother; 2013 Jun; 9(6):1254-62. PubMed ID: 23434737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.
    Leroux-Roels G; Maes C; De Boever F; Traskine M; Rüggeberg JU; Borys D
    Vaccine; 2014 Nov; 32(50):6838-46. PubMed ID: 24607003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems.
    Precioso AR; Miraglia JL; Campos LM; Goulart AC; Timenetsky Mdo C; Cardoso MR; Luna E; Mondini G; Guedes Jda S; Raw I
    Vaccine; 2011 Nov; 29(48):8974-81. PubMed ID: 21945258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
    Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
    Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages.
    Tambyah PA; Oon J; Asli R; Kristanto W; Hwa SH; Vang F; Karwal L; Fuchs J; Santangelo JD; Gordon GS; Thomson C; Rao R; Dean H; Das SC; Stinchcomb DT
    Vaccine; 2019 Jul; 37(31):4344-4353. PubMed ID: 31230881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.
    Rupp R; Luckasen GJ; Kirstein JL; Osorio JE; Santangelo JD; Raanan M; Smith MK; Wallace D; Gordon GS; Stinchcomb DT
    Vaccine; 2015 Nov; 33(46):6351-9. PubMed ID: 26384447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The endemic GII.4 norovirus-like-particle induced-antibody lacks of cross-reactivity against the epidemic GII.17 strain.
    Du J; Gu Q; Liu Y; Li Q; Guo T; Liu Y
    J Med Virol; 2021 Jun; 93(6):3974-3979. PubMed ID: 32869863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial.
    Li YP; Liang ZL; Gao Q; Huang LR; Mao QY; Wen SQ; Liu Y; Yin WD; Li RC; Wang JZ
    Vaccine; 2012 May; 30(22):3295-303. PubMed ID: 22426327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.